Although kidney failure persisted, there was no evidence of the recurrence in subsequent hospitalizations following the cessation of IFN-β.[15] There are also other case reports of renal TMA associated with the use of IFN-β-1a in MS.[18–20]. The gene discussed is IFNB1; the disease is myeloid sarcoma.